Mustang Bio, Inc. (MBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.39
- As of
Kresmion compiles this page from MBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MUSTANG BIO, INC. (MBIO): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full MBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the MBIO dossierActive events for MBIO
- high13F: large reduction
TWO SIGMA INVESTMENTS, LP cut 58% of MBIO (2026Q1)
- mediumEarnings below estimates
Q3-2023: Missed consensus by 7.7% - EPS $-70 vs $-65.025 estimate
- mediumEarnings above estimates
Q4-2023: Beat consensus by 36.6% - EPS $-43 vs $-67.83 estimate
- mediumEarnings above estimates
Q3-2024: Beat consensus by 69.8% - EPS $-2 vs $-6.63 estimate
- mediumEarnings below estimates
Q4-2024: Missed consensus by 365.1% - EPS $-37.95 vs $-8.16 estimate
FREE, NO ACCOUNT
Every event on MBIO, as it fires
You are seeing 5 of 9 events recorded on MBIO since 2026-06-02.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, MBIO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on MBIO
MBIO against its peers
MBIO's return on equity of -20.2% ranks in the 88th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-03-31.
| Metric | MBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 101551 | n/a | 6 |
| Operating margin | n/a | -3769.1% | n/a | 6 |
| Net margin | n/a | -4141.7% | n/a | 6 |
| Return on equity | -20.2% | -149.4% | 88 | 11 |
| 1 year | -67.5% | -92.7% | 89 | 13 |
Peers (17): ERNA, EOCN, SILO, JUNS, CMND, VSBC, LSBCF.D, DCOY, BCAB, TRAW, ABPO, CLDI, CVKD, APVO, VIVS, DRMA, REVB. Left out: NRSN (no annual filing), VCNX (period gap), BIXT (no annual filing), LIMN (no annual filing), GPLL (period gap), BVAXF (no annual filing), AGNPF (no annual filing), XTLB (period gap). Fiscal periods ending between 2025-03-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (MBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in MBIO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on MBIO in the last 180 days.
Upstream: SEC EDGAR filings for MBIO
Kresmion, "MUSTANG BIO, INC. (MBIO) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/MBIO. Upstream data: SEC EDGAR filings for MBIO.
Link to this data (HTML):
<a href="https://kresmion.com/research/MBIO">MUSTANG BIO, INC. (MBIO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow MBIO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to MBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.